EcoDrugPlus

Polo Like Kinase 4

Ensembl ID : ENSCGOG00000010757
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSCGOG00000017502
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSCGOG00000024608
Gene Symbol: PARP2
3 Cross references
186 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSCGOG00000000703
Gene Symbol: PORCN
3 Cross references
195 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSCGOG00000003217
Gene Symbol: PORCN
3 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSCGOG00000022959
Gene Symbol: KCNMA1
3 Cross references
244 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSCGOG00000004266
Gene Symbol: KCNMA1
3 Cross references
227 Possible Orthologues:

Potassium Channel Subfamily K Member 2-Like

Ensembl ID : ENSCGOG00000010602
Gene Symbol: LOC115003845
3 Cross references
214 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSCGOG00000009734
Gene Symbol: KCNJ11
3 Cross references
189 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSCGOG00000004532
Gene Symbol: KCNJ2
3 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSCGOG00000024583
Gene Symbol: KCNJ3
3 Cross references
222 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSCGOG00000016546
Gene Symbol: KCNJ5
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).